Merck, one of the world’s leading vaccine makers, is ending its Covid-19 vaccine development after its two candidates failed to elicit immune responses as strong as those seen from shots that are already available.
The US pharmaceutical company also said on Monday that its phase 1 trials showed participants’ response was not as robust as the immune response seen in recovered Covid-19 patients. There were no significant safety issues.
Shares in Merck fell 1.8 per cent to $79.51 in pre-market trading in New York as the company said it would record an unspecified charge in the fourth quarter.
您已阅读34%（597字），剩余66%（1159字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。